OBJECTIVE: To describe pregnancy outcomes for pregnant women with sickle cell disease (SCD) receiving prophylactic transfusions. STUDY DESIGN: This retrospective case-control study compared pregnancy outcomes among women with SCD receiving prophylactic transfusions and women without any hemoglobinopathy, matched for ethnicity, parity, age and hospital. RESULTS: The study included two groups of pregnancies: 128 in women with SCD (95 with SS phenotype and 33 with SC) and 128 in women with AA phenotype. No woman died. Two perinatal deaths (2.1%) and five alloimmunizations (5.3%) occurred, all in the SS group. Compared with the control group, HbSS disease was more often associated with pre-eclampsia (9.4% versus 2.3%, p=.03), preterm delivery (15.8% versus 6.2%, p=.01), birth weight <10th percentile (13.7% versus 3.9%, p=.008) and caesarean delivery (73.6% versus 26.4%, p<.01). CONCLUSION: Despite prophylactic blood transfusions, SCD remains a severe complicating factor in pregnancy. The policy of systematic transfusions should be analyzed in a sufficiently large randomized trial.
OBJECTIVE: To describe pregnancy outcomes for pregnant women with sickle cell disease (SCD) receiving prophylactic transfusions. STUDY DESIGN: This retrospective case-control study compared pregnancy outcomes among women with SCD receiving prophylactic transfusions and women without any hemoglobinopathy, matched for ethnicity, parity, age and hospital. RESULTS: The study included two groups of pregnancies: 128 in women with SCD (95 with SS phenotype and 33 with SC) and 128 in women with AA phenotype. No woman died. Two perinatal deaths (2.1%) and five alloimmunizations (5.3%) occurred, all in the SS group. Compared with the control group, HbSS disease was more often associated with pre-eclampsia (9.4% versus 2.3%, p=.03), preterm delivery (15.8% versus 6.2%, p=.01), birth weight <10th percentile (13.7% versus 3.9%, p=.008) and caesarean delivery (73.6% versus 26.4%, p<.01). CONCLUSION: Despite prophylactic blood transfusions, SCD remains a severe complicating factor in pregnancy. The policy of systematic transfusions should be analyzed in a sufficiently large randomized trial.
Authors: Nana O Wilson; Fatou K Ceesay; Jacqueline M Hibbert; Adel Driss; Samuel A Obed; Andrew A Adjei; Richard K Gyasi; Winston A Anderson; Jonathan K Stiles Journal: Am J Trop Med Hyg Date: 2012-06 Impact factor: 2.345
Authors: Samuel A Oppong; Eugenia V Asare; Edeghonghon Olayemi; Theodore Boafor; Yvonne Dei-Adomakoh; Alim Swarry-Deen; Enoch Mensah; Yvonne Osei-Bonsu; Selina Crabbe; Latif Musah; Charles Hayfron-Benjamin; Brittany Covert; Adetola A Kassim; Andra James; Mark Rodeghier; Carolyn Audet; Michael R DeBaun Journal: Am J Hematol Date: 2018-12-05 Impact factor: 10.047